Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2215)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 04.05.24 00:07:47 von
neuester Beitrag 04.05.24 00:07:47 von
Beiträge: 22.842
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 1
Gesamt: 1.233.243
Gesamt: 1.233.243
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
4,5660
EUR
+3,88 %
+0,1705 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
01.05.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 41,21 | +28,74 | |
| 8,7200 | +28,42 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 8,0200 | +19,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9999 | -19,36 | |
| 3,5200 | -21,43 | |
| 3,5000 | -26,24 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
bislang hat NVAX immer subito zurückgeschrieben, irgendwie denk ich dass heut was geht....Bauchgefühl eben
hier noch die zwischenzeitliche Antwort von NVAX, soll mal nur positive Pressemitteilung verkünden
:
Hello ....
I am aware of your email. I will respond but have some pressing deadlines. Thank you for the understanding
Kind regards
Tricia
Tricia J. Richardson
Senior Manager, Investor Relations
Novavax, Inc.
9920 Belward Campus Drive
Rockville, MD 20850
Direct Line: 240 268 2031
Direct e-fax: 240 268 2131
email: trichardson@novavax.com
www.novavax.com
:Hello ....
I am aware of your email. I will respond but have some pressing deadlines. Thank you for the understanding
Kind regards
Tricia
Tricia J. Richardson
Senior Manager, Investor Relations
Novavax, Inc.
9920 Belward Campus Drive
Rockville, MD 20850
Direct Line: 240 268 2031
Direct e-fax: 240 268 2131
email: trichardson@novavax.com
www.novavax.com
Nix mehr mit den gewohnten Updates, die WHO stellt die bisherige kontinuierliche Berichterstattung mit den bisherigen Updates ein.
Anscheinend nimmt das Tempo der Infektionen derartig zu, dass die WHO mit ihren Updates nicht mehr hinterher kommt !
Meine Meinung: Sollte der Virus zu einer gefährlichen Variante mutieren, stehen wir vor einer globalen Katastrophe !
---------------------------------------------------------
Pandemic (H1N1) 2009 briefing note 3
Changes in reporting requirements for pandemic (H1N1) 2009 virus infection
16 JULY 2009 | GENEVA -- As the 2009 pandemic evolves, the data needed for risk assessment, both within affected countries and at the global level, are also changing.
At this point, further spread of the pandemic, within affected countries and to new countries, is considered inevitable.
This assumption is fully backed by experience. The 2009 influenza pandemic has spread internationally with unprecedented speed. In past pandemics, influenza viruses have needed more than six months to spread as widely as the new H1N1 virus has spread in less than six weeks.
The increasing number of cases in many countries with sustained community transmission is making it extremely difficult, if not impossible, for countries to try and confirm them through laboratory testing. Moreover, the counting of individual cases is now no longer essential in such countries for monitoring either the level or nature of the risk posed by the pandemic virus or to guide implementation of the most appropriate response measures.
Monitoring still needed
This pandemic has been characterized, to date, by the mildness of symptoms in the overwhelming majority of patients, who usually recover, even without medical treatment, within a week of the onset of symptoms. However, there is still an ongoing need in all countries to closely monitor unusual events, such as clusters of cases of severe or fatal pandemic (H1N1) 2009 virus infection, clusters of respiratory illness requiring hospitalization, or unexplained or unusual clinical patterns associated with serious or fatal cases.
Other potential signals of change in the currently prevailing pattern include unexpected, unusual or notable changes in patterns of transmission. Signals to be vigilant for include spikes in rates of absenteeism from schools or workplaces, or a more severe disease pattern, as suggested by, for example, a surge in emergency department visits.
In general, indications that health services are having difficulty coping with cases mean that such systems are under stress but they may also be a signal of increasing cases or a more severe clinical picture.
A strategy that concentrates on the detection, laboratory confirmation and investigation of all cases, including those with mild illness, is extremely resource-intensive. In some countries, this strategy is absorbing most national laboratory and response capacity, leaving little capacity for the monitoring and investigation of severe cases and other exceptional events.
Regular updates on newly affected countries
For all of these reasons, WHO will no longer issue the global tables showing the numbers of confirmed cases for all countries. However, as part of continued efforts to document the global spread of the H1N1 pandemic, regular updates will be provided describing the situation in the newly affected countries. WHO will continue to request that these countries report the first confirmed cases and, as far as feasible, provide weekly aggregated case numbers and descriptive epidemiology of the early cases.
For countries already experiencing community-wide transmission, the focus of surveillance activities will shift to reporting against the established indicators for the monitoring of seasonal influenza activity. Those countries are no longer required to submit regular reports of individual laboratory-confirmed cases and deaths to WHO.
Monitoring the virological characteristics of the pandemic virus will be important throughout the pandemic and some countries have well-established laboratory-based surveillance systems in place already for seasonal influenza virus monitoring. Even in countries with limited laboratory capacity, WHO recommends that the initial virological assessment is followed by the testing of at least 10 samples per week in order to confirm that disease activity is due to the pandemic virus and to monitor changes in the virus that may be important for case management and vaccine development.
Updated WHO guidelines for global surveillance reflect in greater detail these recommended changes, in line with reporting requirements set out in the International Health Regulations.
RELATED LINKS
Interim WHO guidance for the surveillance of human infection with A(H1N1) virus
10 July 2009
--------------------------------------------
Ich denke, die WHO will einfach nur Panik vermeiden,
da bei Veröffentlichung der Zahlen und der Schnelligkeit der
Verbreitung ohne weiteres ein wirtschaftlicher Kollaps drohen könnte...
gruß
massel
Anscheinend nimmt das Tempo der Infektionen derartig zu, dass die WHO mit ihren Updates nicht mehr hinterher kommt !
Meine Meinung: Sollte der Virus zu einer gefährlichen Variante mutieren, stehen wir vor einer globalen Katastrophe !
---------------------------------------------------------
Pandemic (H1N1) 2009 briefing note 3
Changes in reporting requirements for pandemic (H1N1) 2009 virus infection
16 JULY 2009 | GENEVA -- As the 2009 pandemic evolves, the data needed for risk assessment, both within affected countries and at the global level, are also changing.
At this point, further spread of the pandemic, within affected countries and to new countries, is considered inevitable.
This assumption is fully backed by experience. The 2009 influenza pandemic has spread internationally with unprecedented speed. In past pandemics, influenza viruses have needed more than six months to spread as widely as the new H1N1 virus has spread in less than six weeks.
The increasing number of cases in many countries with sustained community transmission is making it extremely difficult, if not impossible, for countries to try and confirm them through laboratory testing. Moreover, the counting of individual cases is now no longer essential in such countries for monitoring either the level or nature of the risk posed by the pandemic virus or to guide implementation of the most appropriate response measures.
Monitoring still needed
This pandemic has been characterized, to date, by the mildness of symptoms in the overwhelming majority of patients, who usually recover, even without medical treatment, within a week of the onset of symptoms. However, there is still an ongoing need in all countries to closely monitor unusual events, such as clusters of cases of severe or fatal pandemic (H1N1) 2009 virus infection, clusters of respiratory illness requiring hospitalization, or unexplained or unusual clinical patterns associated with serious or fatal cases.
Other potential signals of change in the currently prevailing pattern include unexpected, unusual or notable changes in patterns of transmission. Signals to be vigilant for include spikes in rates of absenteeism from schools or workplaces, or a more severe disease pattern, as suggested by, for example, a surge in emergency department visits.
In general, indications that health services are having difficulty coping with cases mean that such systems are under stress but they may also be a signal of increasing cases or a more severe clinical picture.
A strategy that concentrates on the detection, laboratory confirmation and investigation of all cases, including those with mild illness, is extremely resource-intensive. In some countries, this strategy is absorbing most national laboratory and response capacity, leaving little capacity for the monitoring and investigation of severe cases and other exceptional events.
Regular updates on newly affected countries
For all of these reasons, WHO will no longer issue the global tables showing the numbers of confirmed cases for all countries. However, as part of continued efforts to document the global spread of the H1N1 pandemic, regular updates will be provided describing the situation in the newly affected countries. WHO will continue to request that these countries report the first confirmed cases and, as far as feasible, provide weekly aggregated case numbers and descriptive epidemiology of the early cases.
For countries already experiencing community-wide transmission, the focus of surveillance activities will shift to reporting against the established indicators for the monitoring of seasonal influenza activity. Those countries are no longer required to submit regular reports of individual laboratory-confirmed cases and deaths to WHO.
Monitoring the virological characteristics of the pandemic virus will be important throughout the pandemic and some countries have well-established laboratory-based surveillance systems in place already for seasonal influenza virus monitoring. Even in countries with limited laboratory capacity, WHO recommends that the initial virological assessment is followed by the testing of at least 10 samples per week in order to confirm that disease activity is due to the pandemic virus and to monitor changes in the virus that may be important for case management and vaccine development.
Updated WHO guidelines for global surveillance reflect in greater detail these recommended changes, in line with reporting requirements set out in the International Health Regulations.
RELATED LINKS
Interim WHO guidance for the surveillance of human infection with A(H1N1) virus
10 July 2009
--------------------------------------------
Ich denke, die WHO will einfach nur Panik vermeiden,
da bei Veröffentlichung der Zahlen und der Schnelligkeit der
Verbreitung ohne weiteres ein wirtschaftlicher Kollaps drohen könnte...
gruß
massel
Antwort auf Beitrag Nr.: 37.586.704 von vanillamilkshake am 16.07.09 16:56:01der meinte doch er geht freitag in urlaub für 2 wochen?!
novavax sieht wieder gut aus heute!!
novavax sieht wieder gut aus heute!!
Antwort auf Beitrag Nr.: 37.586.704 von vanillamilkshake am 16.07.09 16:56:01der hat glaub verkauft.......
Trading Spotlight
Antwort auf Beitrag Nr.: 37.586.363 von 360 am 16.07.09 16:14:52Laut Meldung:
$2.5163, resulting in 1,016,939 shares of common stock.
Also ca. 1 Mio Shares á 2,51 USD
Man kann wohl davon ausgehen, dass die Änderung am 15. Juli wirksam wurde, es aber ein paar Tage Zeit braucht, bis die Depotverwalter die Wertapiere umgebucht haben.
Ich weiß nicht, wann die Anleihen emmitiert wurden und wie zufrieden die Investoren mit dem 50% Umtausch sind (die Option lag ja bei NVAX), also entsprechend die Entwicklung von NVAX sehen. Wenn der Konsens Deinem Analystenkommentar entspricht, wird wohl kein großer Verkaufsdruck entstehen.
Ich werd NVAX erstmal "nur" beobachten, da der Schweinegrippe-Erreger ein erhebliches pandemisches Potential besitzt, aber die Entwicklung von NVAX für mich erstmal noch unsicher ist
Mich würde mal der Stand der Dinge bei anderen Vakzin-Smallcaps interessieren, bin derzeit nur bei NVAX im Bilde...
------
Was macht Massel eigentlich???
$2.5163, resulting in 1,016,939 shares of common stock.
Also ca. 1 Mio Shares á 2,51 USD
Man kann wohl davon ausgehen, dass die Änderung am 15. Juli wirksam wurde, es aber ein paar Tage Zeit braucht, bis die Depotverwalter die Wertapiere umgebucht haben.
Ich weiß nicht, wann die Anleihen emmitiert wurden und wie zufrieden die Investoren mit dem 50% Umtausch sind (die Option lag ja bei NVAX), also entsprechend die Entwicklung von NVAX sehen. Wenn der Konsens Deinem Analystenkommentar entspricht, wird wohl kein großer Verkaufsdruck entstehen.
Ich werd NVAX erstmal "nur" beobachten, da der Schweinegrippe-Erreger ein erhebliches pandemisches Potential besitzt, aber die Entwicklung von NVAX für mich erstmal noch unsicher ist
Mich würde mal der Stand der Dinge bei anderen Vakzin-Smallcaps interessieren, bin derzeit nur bei NVAX im Bilde...
------
Was macht Massel eigentlich???
Antwort auf Beitrag Nr.: 37.585.202 von vanillamilkshake am 16.07.09 14:10:20weisst Du zu welchem Kurs sie in Aktien umgetauscht haben
Antwort auf Beitrag Nr.: 37.585.202 von vanillamilkshake am 16.07.09 14:10:20ja und die kleine Verwässerung bringt uns auch die Antwort, weshalb der Kurs etwas sehr seitlich verläuft. Bin nach wie vor mehr wie sicher, die richtige Strategie mit NVAX zu fahren. Habe übrigens die Analysten angeschrieben, welche mich eingedeckt haben mit Infos über die Bewertung von NVAX
Novavax Inc. (NVAX)
Price: $2.58 (07/10/2009), Price Target: $5.00, Market Cap(MM): $231.9,
Rating: Market Outperform
Elemer Piros, Ph.D., Senior Biotechnology Analyst 212-430-1754 epiros@rodm.com
Boris Peaker, Ph.D., Associate Biotechnology Analyst 212-430-1778 bpeaker@rodm.com
Recombinant Vaccine RFP Presents An Opportunity For Novavax
Key Points
l Final RFP for recombinant vaccine has been posted
l Government will invest in development of technology with completed Phase 1 study that is able to produce 50MM doses of vaccine
within 6 months
l We believe that Novavax’s technology meets BARDA's basic requirements and is highly competitive for this award
Novavax Is Uniquely Positioned To Address BARDA’s Need
On Friday, July 10th, the office of Biomedical Advanced Research and Development Authority released an official Request for Proposal
(RFP) for the development of recombinant influenza vaccine. Specifically, the RFP focuses on technologies that can produce
recombinant pandemic and seasonal vaccines, and lists Virus-Like Particles (VLP) as one such potential technology. Additionally, the
proposed vaccine platform must have completed Phase 1 safety studies, be manufactured in a US-based facility, produce the first lot of
vaccine within 12 weeks of the pandemic onset, and be scalable enough to produce 50MM doses within 6 months. In our view Novavax’s
VLP platform meets these requirements. Novavax’s current US-based facility can produce 10MM doses of vaccine within six months, but
due to the easy scalability of the disposable reactor technology, we believe that this production capacity can easily be increased to meet
BARDA’s requirement. In addition to the rapid manufacturing scalability and low cost of the VLP-based vaccines, Novavax completed
Phase 1 studies in both seasonal and pandemic influenza for its vaccine. Additionally, we believe that the recent partnership with the
Spanish government will further highlight Novavax’s VLP vaccine technology as a viable platform to address BARDA’s vaccine needs.
Link to final RFP:
https://www.fbo.gov/index?s=opportunity&mode=form&id=7e7f2e4…
Reiterate Outperform Rating And $5 Price Target
Although the RFP does not highlight specific economics of a potential award, we believe that potential US government sponsorship of the
development of Novavax’s VLP platform may provide significant upside to investors. We arrive at our price target without assuming a
BARDA award and our recent reduction in R&D spending is due only to the recent deal with ROVI pharmaceuticals and the Spanish
government. Our 12-month target price is based on our estimated EPS of $1.07 in 2013AX, stell mach einen Teil rein....
Novavax Inc. (NVAX)
Price: $2.58 (07/10/2009), Price Target: $5.00, Market Cap(MM): $231.9,
Rating: Market Outperform
Elemer Piros, Ph.D., Senior Biotechnology Analyst 212-430-1754 epiros@rodm.com
Boris Peaker, Ph.D., Associate Biotechnology Analyst 212-430-1778 bpeaker@rodm.com
Recombinant Vaccine RFP Presents An Opportunity For Novavax
Key Points
l Final RFP for recombinant vaccine has been posted
l Government will invest in development of technology with completed Phase 1 study that is able to produce 50MM doses of vaccine
within 6 months
l We believe that Novavax’s technology meets BARDA's basic requirements and is highly competitive for this award
Novavax Is Uniquely Positioned To Address BARDA’s Need
On Friday, July 10th, the office of Biomedical Advanced Research and Development Authority released an official Request for Proposal
(RFP) for the development of recombinant influenza vaccine. Specifically, the RFP focuses on technologies that can produce
recombinant pandemic and seasonal vaccines, and lists Virus-Like Particles (VLP) as one such potential technology. Additionally, the
proposed vaccine platform must have completed Phase 1 safety studies, be manufactured in a US-based facility, produce the first lot of
vaccine within 12 weeks of the pandemic onset, and be scalable enough to produce 50MM doses within 6 months. In our view Novavax’s
VLP platform meets these requirements. Novavax’s current US-based facility can produce 10MM doses of vaccine within six months, but
due to the easy scalability of the disposable reactor technology, we believe that this production capacity can easily be increased to meet
BARDA’s requirement. In addition to the rapid manufacturing scalability and low cost of the VLP-based vaccines, Novavax completed
Phase 1 studies in both seasonal and pandemic influenza for its vaccine. Additionally, we believe that the recent partnership with the
Spanish government will further highlight Novavax’s VLP vaccine technology as a viable platform to address BARDA’s vaccine needs.
Link to final RFP:
https://www.fbo.gov/index?s=opportunity&mode=form&id=7e7f2e4…
Reiterate Outperform Rating And $5 Price Target
Although the RFP does not highlight specific economics of a potential award, we believe that potential US government sponsorship of the
development of Novavax’s VLP platform may provide significant upside to investors. We arrive at our price target without assuming a
BARDA award and our recent reduction in R&D spending is due only to the recent deal with ROVI pharmaceuticals and the Spanish
government. Our 12-month target price is based on our estimated EPS of $1.07 in 2013AX, stell mach einen Teil rein....
Antwort auf Beitrag Nr.: 37.580.289 von 360 am 15.07.09 20:05:51
Mmmh. Mit dem Umtausch in Aktien is natürlich ne geringfügige Kursverwässerung mit einher gegangen, aber dadurch haben sie sich finanziell ein kleines Polster zugelegt... Is fundamental sehr begrüßenswert.
Mkt. Cap. (Mil) $ 245.34
Shares Out (Mil) 89.87
Das Statement von Rahul Shingvi ist sehr interessant.
Mmmh. Mit dem Umtausch in Aktien is natürlich ne geringfügige Kursverwässerung mit einher gegangen, aber dadurch haben sie sich finanziell ein kleines Polster zugelegt... Is fundamental sehr begrüßenswert.
Mkt. Cap. (Mil) $ 245.34
Shares Out (Mil) 89.87
Das Statement von Rahul Shingvi ist sehr interessant.
richtig 360!!!
ürsprünglich bin ich hier eingestiegen zum zocken,
der richtige zock bleibt aber irgendwie aus und novavax zeigt ein gutes bild für ein langfristiges investment...vlt wird es das ja wirklich noch
ürsprünglich bin ich hier eingestiegen zum zocken,
der richtige zock bleibt aber irgendwie aus und novavax zeigt ein gutes bild für ein langfristiges investment...vlt wird es das ja wirklich noch
Durchsuchen
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |